Granules India delivered impressive fourth quarter results with net profit surging 32.6% year-on-year to ₹201.5 crore from ₹152 crore in the corresponding quarter last year. According to reports from CNBC TV18, the pharmaceutical company's revenue grew 22.8% to ₹1,470.6 crore from ₹1,197.4 crore during the same quarter last year. The company's EBITDA increased by 39.6% to ₹352 crore from ₹252 crore year-ago, while EBITDA margin expanded by nearly 300 basis points to 23.9% from 21% in the previous year.
The strong financial results drove Granules India shares to trade at a record high of ₹721, gaining 2.2% during the session. As reported by CNBC TV18, shares have risen 13% so far in April, marking the best month for the stock since May last year when it gained 16%. The stock recovered from early session lows to reach these highs in response to the positive quarterly results. Latest market data shows the stock trading with volumes of 148,546 shares, compared to its five day average of 65,393 shares, representing a 127.16% increase in trading volume.
The board of Granules India has recommended a final dividend of ₹1.75 per share for the quarter. According to reports from CNBC TV18, in December 2025, the company's board had approved the issuance of 2.5 crore warrants each convertible to fully paid up equity shares for a total consideration of ₹1,462.5 crore. During the quarter, the company received an aggregate of ₹365.6 crore on February 23, which represents 25% of the total consideration for the warrant issue.
